Close



Mar 8, 2024 07:00AM
Mar 7, 2024 06:02AM
Mar 7, 2024 06:00AM
Feb 28, 2024 07:05AM
Jan 8, 2024 07:49AM
Jan 8, 2024 07:45AM
Dec 14, 2023 07:45AM Mind Medicine (MNMD) to Resume Trading at 8 a.m. Following Positive Data from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
Dec 14, 2023 07:31AM
Dec 14, 2023 07:30AM
Jun 15, 2023 04:23PM
Jun 9, 2023 04:18PM
Jun 9, 2023 04:17PM
Jun 8, 2023 11:30AM
Jun 7, 2023 08:08AM FCM Plans for Mind Medicine's (MNMD) MM-120 (LSD) FDA Approval in 2026 And Extends Share Lockup Until June 15, 2026
Jun 7, 2023 08:07AM
Jun 5, 2023 06:19AM
Jun 5, 2023 06:19AM
Jun 2, 2023 04:17PM
May 25, 2023 04:57PM
May 25, 2023 08:04AM
May 25, 2023 08:00AM MindMed Publishes Report by Leading FDA Experts Validating MindMed’s MM-120 Drug Development Strategy
May 15, 2023 08:24AM
May 5, 2023 08:08AM
May 2, 2023 08:00AM
Nov 3, 2022 08:08AM
Nov 3, 2022 08:08AM
Aug 12, 2022 07:30AM
Apr 5, 2022 07:31AM Mind Medicine (MNMD) Appoints Francois Lilienthal as COO
Apr 5, 2022 07:30AM
Mar 28, 2022 07:30AM
Mar 16, 2022 08:00AM
Jan 25, 2022 07:31AM
Jan 25, 2022 07:30AM
Jan 18, 2022 07:30AM
Dec 21, 2021 07:31AM Mind Medicine (MNMD) Announces Clinical Hold on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety Disorder
Dec 21, 2021 07:30AM
Dec 9, 2021 07:31AM
Dec 9, 2021 07:30AM
Aug 10, 2021 07:30AM
Aug 3, 2021 07:30AM
May 17, 2021 07:32AM
May 17, 2021 07:30AM MindMed Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial
May 14, 2021 07:32AM
May 13, 2021 07:30AM
May 5, 2021 07:30AM

251,761 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All